Gastrointestinal Stromal Tumors

Glivec recommended as first line management for gastrointestinal stromal tumors

Published in Cancer Weekly, September 7th, 2004

The National Institute for Clinical Excellence (NICE) has announced its final recommendations on the use of Glivec as first-line management of patients with KIT (CD117) positive unresectable and/or metastatic gastrointestinal stromal tumors (GISTs).

Glivec, the only treatment currently available for the disease, is now fully approved by NICE for the first-line management of patients with GISTs and chronic myeloid leukemia in all stages of the disease and will be fully funded by the National Institutes of Health in accordance with all its licensed indications as recommended by NICE.

Professor Ian Judson, consultant medical oncologist, Royal Marsden...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry